breast
uteru
type
compound
call
select
estrogen
receptor
modul
serm
raloxifen
secondgener
benzothiophenederiv
serm
sole
compound
approv
prevent
treatment
postmenopaus
osteoporosi
certain
random
clinic
trial
demonstr
raloxifen
decreas
fractur
risk
vertebra
postmenopaus
osteoporosi
led
side
effect
thromboembol
disord
problem
turn
stimul
develop
next
gener
serm
suitabl
chronic
therapi
raloxifen
recent
synthes
seri
raloxifen
deriv
benzothiophen
moieti
replac
benzofuran
group
deriv
screen
bone
resorpt
inhibit
vitro
assay
one
deriv
z
aminobenzo
b
furan
code
found
activ
e
studi
examin
mechan
action
antiosteoporosi
activ
evalu
serm
follow
reagent
obtain
indic
sourc
invitrogen
auckland
new
zealand
fb
thermo
fisher
scientif
waltham
usa
receptor
activ
nuclear
ligand
rankl
orient
yeast
co
ltd
tokyo
mcsf
r
system
inc
minneapoli
mn
usa
tocri
ellisvil
mo
usa
nacalai
tesqu
kyoto
laboratori
anim
purchas
shizuoka
laboratori
anim
center
shizuoka
synthes
ohishi
cowork
studi
monocyterich
fraction
prepar
tibia
femora
ddi
mice
n
bone
marrow
cell
obtain
long
bone
suspend
layer
onto
ficollpaqu
ge
healthcar
uk
ltd
buckinghamshir
uk
centrifug
fraction
gel
supernat
collect
monocyterich
fraction
cell
cultur
h
contain
ngml
mcsf
fb
subsequ
nonadher
cell
cellswel
inocul
biocoat
osteolog
disc
bd
bioscienc
san
jose
ca
usa
contain
fb
ngml
mcsf
ngml
rankl
incub
day
e
compound
ad
medium
begin
cultur
cultiv
disc
rins
distil
water
cell
dislodg
bleach
solut
naoh
resorpt
lacuna
disc
evalu
phase
contrast
microscopi
area
lacuna
measur
osteoclast
resorpt
pit
forti
wistar
femal
rat
receiv
ovariectomi
ovx
sham
oper
nembut
anesthesia
divid
group
treat
describ
tabl
e
dissolv
suspend
sesam
oil
wako
pure
chem
inc
osaka
inject
subcutan
pm
day
per
week
monday
wednesday
friday
saturday
period
start
one
week
surgeri
experi
involv
anim
review
approv
committe
anim
experi
hiroshima
intern
univers
rat
sacrif
exsanguin
femor
vein
nembut
anesthesia
tibia
femora
uteri
surgic
remov
right
tibia
kept
icecold
ethanol
solut
measur
bone
miner
content
bmc
bone
miner
densiti
bmd
left
tibia
embed
watersolubl
methacryl
resin
wako
pure
chem
obtain
longitudin
slice
femora
evalu
mechan
strength
uteri
proxim
end
vagina
fallopian
tube
wash
icecold
salin
wettissu
weight
measur
fixat
neutral
formaldehyd
uteri
embed
paraffin
section
histolog
evalu
bmc
bmd
estim
dual
energi
xray
absorptiometri
aloka
osaka
bone
area
assess
entir
proxim
end
right
tibia
dual
energi
xray
absorptiometri
analys
kev
conduct
mm
long
proxim
end
right
femur
dissect
place
femor
neck
holder
osakarika
osaka
fix
distal
region
ostoron
ii
gc
oc
tokyo
femur
head
press
break
point
max
kg
constant
speed
mm
min
fractur
load
n
fractur
energi
mj
calcul
indic
mechan
strength
use
bone
break
strength
tester
muromachi
kikai
co
tokyo
left
femur
mount
mm
threepoint
bend
test
measur
mechan
strength
femor
center
data
express
mean
standard
error
sem
statist
analys
perform
fisher
least
signific
differ
test
p
defin
signific
chemic
structur
shown
fig
compound
favor
balanc
lipophil
hydrophil
properti
benzo
b
furan
deriv
fuse
aromat
ring
exhibit
certain
uniqu
area
lacuna
calcul
use
imag
analysi
softwar
photoshop
adob
osteoclast
bone
resorpt
estim
percentag
control
averag
area
lacuna
plate
standard
error
control
mm
respect
n
p
p
indic
signific
differ
control
p
group
aa
p
group
bioactiv
antihuman
coronaviru
activ
inhibit
express
day
osteoclastlik
multinuclear
giant
cell
observ
cultur
bone
marrow
cell
treat
rankl
mcsf
fig
number
lacuna
believ
excav
osteoclastlik
multinuclear
giant
cell
seen
surfac
miner
calcium
phosphat
thin
film
coat
cultur
vessel
fig
e
nm
suppress
format
lacuna
fig
nm
inhibit
suppress
effect
lacuna
format
osteoclastlik
multinuclear
giant
cell
fig
exert
similar
antagonist
effect
suppress
effect
e
fig
nine
week
postovx
bmc
proxim
end
tibia
significantli
diminish
e
sc
prevent
ovxinduc
declin
bmc
fig
sc
also
significantli
inhibit
ovxinduc
osteopenia
fig
chang
bmd
correl
bmc
fig
decreas
bmc
bmd
ovx
detect
entir
tibia
fig
b
observ
undecalcifi
bone
section
indic
cancel
bone
volum
decreas
trabecular
structur
cancel
bone
disappear
proxim
tibia
metaphysi
postovx
fig
e
suppress
ovxinduc
decreas
cancel
bone
volum
destruct
trabecular
structur
fig
ovx
significantli
decreas
fractur
load
femor
neck
e
complet
prevent
declin
fig
even
low
dose
protect
decreas
mechan
strength
femor
neck
potent
e
fig
chang
fractur
energi
femor
neck
similar
fractur
load
signific
chang
observ
fig
sham
ovx
group
threepoint
bend
test
femor
shaft
fail
detect
ovxinduc
loss
mechan
strength
fig
c
e
administr
ovxinduc
decreas
uterin
weight
complet
prevent
fig
wherea
effect
ovxinduc
uterin
atrophi
fig
histolog
examin
paraffin
section
show
endometri
dystrophi
caus
ovx
wherea
e
potent
hypertroph
effect
fig
contrast
e
stimul
effect
endometrium
fig
osteoclast
progenitor
cell
bone
marrow
differenti
matur
osteoclast
presenc
rankl
mcsf
vitro
osteoclastlik
multinuclear
giant
cell
appear
day
incub
express
tartrateresist
acid
phosphatas
data
shown
osteoclast
biomark
sever
lacuna
appear
surfac
miner
calcium
phosphat
thinfilm
day
incub
fig
therefor
conclud
osteoclastlik
multinuclear
giant
cell
cultur
system
mediat
bone
inhibit
bone
resorpt
potent
e
inhibitori
effect
lacuna
format
osteoclast
attenu
pure
e
antagonist
similarli
suppress
inhibitori
effect
e
therefor
result
strongli
indic
exert
antibon
resorpt
activ
stimul
estrogen
receptor
er
ovxrat
exhibit
similar
pathophysiolog
chang
bone
metabol
postmenopaus
women
therefor
frequent
use
drug
develop
studi
model
postmenopaus
osteoporosi
evalu
tibial
bone
mass
dual
energi
xray
absorptiometri
show
bone
loss
ovxrat
occur
mainli
proxim
end
histolog
observ
undecalcifi
thin
section
reveal
decreas
bone
mass
result
declin
cancel
bone
volum
disappear
trabecular
structur
proxim
tibia
metaphysi
chang
bone
volum
trabecular
structur
complet
inhibit
e
clinic
studi
indic
degen
chang
cancel
bone
quantiti
qualiti
occur
neck
femora
lumbar
vertebra
caus
nontraumat
fractur
postmenopaus
women
assess
mechan
strength
show
ovx
decreas
fractur
load
femor
neck
e
suppress
ovxinduc
declin
bone
mechan
strength
similar
reduct
fractur
load
detect
femor
shaft
show
decreas
bone
mass
fractur
load
one
main
indic
assess
mechan
strength
therefor
may
also
suppress
ovxinduc
decreas
mechan
strength
bone
e
stimul
reproduct
tissu
increas
risk
uterin
breast
cancer
postmenopaus
women
experi
e
potent
hypertroph
effect
endometrium
contrast
stimul
ovxinduc
uterin
atrophi
result
strongli
indic
sermlik
characterist
osteoprotect
effect
e
well
known
mechan
action
complet
elucid
nakamura
et
al
demonstr
e
activ
matur
osteoclast
induc
apoptosi
stimul
fasfasl
system
genedisrupt
model
ablat
specif
target
differenti
osteoclast
therefor
conclud
ovxinduc
rapid
enhanc
osteoclast
bone
resorpt
could
explain
increas
osteoclast
surviv
e
defici
contrast
robinson
et
al
show
e
exert
osteoprotect
effect
inhibit
ranklstimul
osteoclast
differenti
preliminari
studi
use
osteoporosi
mous
model
show
ovx
decreas
fasl
express
bone
tissu
e
suppress
reduct
fasl
express
ovx
data
shown
therefor
consid
antibon
resorpt
activ
occur
decreas
life
span
osteoclast
mechan
would
includ
apoptot
osteoclast
death
raloxifen
sole
serm
reduc
vertebr
fractur
risk
postmenopaus
women
howev
grow
evid
raloxifen
treatment
effect
fractur
risk
nonvertebr
region
increas
advers
effect
thromboembol
disord
problem
promot
develop
new
gener
serm
benefici
properti
therapi
osteoporosi
conclus
novel
compound
exhibit
sermlik
characterist
may
becom
princip
compound
develop
antiosteoporot
therapi
